Dynamics of liver stiffness measurement and clinical course of primary biliary cholangitis.

Elastography FibroScan Liver stiffness PBC Prognosis Time course

Journal

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
ISSN: 1542-7714
Titre abrégé: Clin Gastroenterol Hepatol
Pays: United States
ID NLM: 101160775

Informations de publication

Date de publication:
15 Jul 2024
Historique:
received: 28 05 2024
accepted: 17 06 2024
medline: 18 7 2024
pubmed: 18 7 2024
entrez: 17 7 2024
Statut: aheadofprint

Résumé

In primary biliary cholangitis (PBC), static liver stiffness measurement (LSM) has proven prognostic value. However, the added prognostic value of LSM time course in this disease remains uncertain. We conducted an international retrospective cohort study among PBC patients treated with ursodeoxycholic acid (UDCA) and followed by vibration-controlled transient elastography (VCTE) between 2003 and 2022. Using joint modeling, the association of LSM trajectory and the incidence of serious clinical events (SCE), defined as cirrhosis complications, liver transplantation (LT) or death, was quantified using the hazard ratio (HR) and its confidence interval (CI). A total of 6,362 LSMs were performed in 3,078 patients (2,007 on UDCA alone; 13% with cirrhosis), in whom 316 SCE occurred over 14,445 person-years (median follow-up, 4.2 years; incidence rate, 21.9 per 1,000 person-years). LSM progressed in 59% of patients (mean 0.39 kPa/year). After adjusting for prognostic factors at baseline, including LSM, any relative change in LSM was associated with a significant variation in SCE risk (p<0.001). For example, the adjusted HRs (95% CI) associated with a 20% annual variation in LSM were 2.13 (1.89 - 2.45) for the increase and 0.40 (0.33 - 0.46) for the decrease. The association between LSM trajectory and SCE risk persisted regardless of treatment response or duration, when patients with cirrhosis were excluded, and when only death or LT was considered. Tracking longitudinal changes in LSM using VCTE provides valuable insights into PBC prognosis, offering a robust predictive measure for the risk of SCE. LSM could be used as a clinically relevant surrogate endpoint in PBC clinical trials.

Sections du résumé

BACKGROUND & AIMS OBJECTIVE
In primary biliary cholangitis (PBC), static liver stiffness measurement (LSM) has proven prognostic value. However, the added prognostic value of LSM time course in this disease remains uncertain.
METHODS METHODS
We conducted an international retrospective cohort study among PBC patients treated with ursodeoxycholic acid (UDCA) and followed by vibration-controlled transient elastography (VCTE) between 2003 and 2022. Using joint modeling, the association of LSM trajectory and the incidence of serious clinical events (SCE), defined as cirrhosis complications, liver transplantation (LT) or death, was quantified using the hazard ratio (HR) and its confidence interval (CI).
RESULTS RESULTS
A total of 6,362 LSMs were performed in 3,078 patients (2,007 on UDCA alone; 13% with cirrhosis), in whom 316 SCE occurred over 14,445 person-years (median follow-up, 4.2 years; incidence rate, 21.9 per 1,000 person-years). LSM progressed in 59% of patients (mean 0.39 kPa/year). After adjusting for prognostic factors at baseline, including LSM, any relative change in LSM was associated with a significant variation in SCE risk (p<0.001). For example, the adjusted HRs (95% CI) associated with a 20% annual variation in LSM were 2.13 (1.89 - 2.45) for the increase and 0.40 (0.33 - 0.46) for the decrease. The association between LSM trajectory and SCE risk persisted regardless of treatment response or duration, when patients with cirrhosis were excluded, and when only death or LT was considered.
CONCLUSIONS CONCLUSIONS
Tracking longitudinal changes in LSM using VCTE provides valuable insights into PBC prognosis, offering a robust predictive measure for the risk of SCE. LSM could be used as a clinically relevant surrogate endpoint in PBC clinical trials.

Identifiants

pubmed: 39019421
pii: S1542-3565(24)00632-3
doi: 10.1016/j.cgh.2024.06.035
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2024. Published by Elsevier Inc.

Auteurs

Laurent Lam (L)

Sorbonne University, Inserm, Pierre Louis Institute of Epidemiology and Public Health, Paris; Public Health Unit, Saint-Antoine Hospital, Assistance Publique - Hôpitaux de Paris, European Reference Network on Hepatological Diseases (ERN Rare-Liver), France.

Pierre-Antoine Soret (PA)

Reference Center for Inflammatory Biliary Diseases and Autoimmune Hepatitis, European Reference Network on Hepatological Diseases (ERN Rare-Liver), Saint-Antoine Hospital, Assistance Publique - Hôpitaux de Paris; Inserm UMR_S938, Saint-Antoine Research Center, Sorbonne University, Paris, France.

Sara Lemoinne (S)

Reference Center for Inflammatory Biliary Diseases and Autoimmune Hepatitis, European Reference Network on Hepatological Diseases (ERN Rare-Liver), Saint-Antoine Hospital, Assistance Publique - Hôpitaux de Paris; Inserm UMR_S938, Saint-Antoine Research Center, Sorbonne University, Paris, France.

Bettina Hansen (B)

Toronto Centre for Liver Disease, University Health Network, University of Toronto, Toronto, Canada; Department of Epidemiology & Biostatistics, Erasmus MC, Rotterdam, the Netherlands.

Gideon Hirschfield (G)

Toronto Centre for Liver Disease, University Health Network, University of Toronto, Toronto, Canada.

Aliya Gulamhusein (A)

Toronto Centre for Liver Disease, University Health Network, University of Toronto, Toronto, Canada.

Aldo J Montano-Loza (AJ)

Division of Gastroenterology and Liver Unit, University of Alberta, Edmonton, Canada.

Ellina Lytvyak (E)

Division of Preventive Medicine, University of Alberta, Edmonton, Alberta, Canada.

Albert Parés (A)

Liver Unit, Hospital Clínic Barcelona, Institut de Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Centro de Investigación Biomédica en Red Enfermedades Hepáticas y Digestivas (CIBEREHD), University of Barcelona, University of Barcelona, European Reference Network on Hepatological Diseases (ERN Rare-Liver), Barcelona, Spain.

Ignasi Olivas (I)

Liver Unit, Hospital Clínic Barcelona, Institut de Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Centro de Investigación Biomédica en Red Enfermedades Hepáticas y Digestivas (CIBEREHD), University of Barcelona, University of Barcelona, European Reference Network on Hepatological Diseases (ERN Rare-Liver), Barcelona, Spain.

Maria-Carlota Londono (MC)

Liver Unit, Hospital Clínic Barcelona, Institut de Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Centro de Investigación Biomédica en Red Enfermedades Hepáticas y Digestivas (CIBEREHD), University of Barcelona, University of Barcelona, European Reference Network on Hepatological Diseases (ERN Rare-Liver), Barcelona, Spain.

Sergio Rodríguez-Tajes (S)

Liver Unit, Hospital Clínic Barcelona, Institut de Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Centro de Investigación Biomédica en Red Enfermedades Hepáticas y Digestivas (CIBEREHD), University of Barcelona, University of Barcelona, European Reference Network on Hepatological Diseases (ERN Rare-Liver), Barcelona, Spain.

John E Eaton (JE)

Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, USA.

Karim T Osman (KT)

Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, USA.

Christoph Schramm (C)

Department of Medicine I and Martin Zeitz Center for Rare Diseases, European Reference Network on Hepatological Diseases (ERN Rare-Liver), University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Marcial Sebode (M)

Department of Medicine I and Martin Zeitz Center for Rare Diseases, European Reference Network on Hepatological Diseases (ERN Rare-Liver), University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Ansgar W Lohse (AW)

Department of Medicine I and Martin Zeitz Center for Rare Diseases, European Reference Network on Hepatological Diseases (ERN Rare-Liver), University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

George Dalekos (G)

Department of Medicine and Research Laboratory of Internal Medicine, National Expertise Center of Greece in Autoimmune Liver Diseases, European Reference Network on Hepatological Diseases (ERN Rare-Liver), General University Hospital, Larissa, Greece.

Nikolaos Gatselis (N)

Department of Medicine and Research Laboratory of Internal Medicine, National Expertise Center of Greece in Autoimmune Liver Diseases, European Reference Network on Hepatological Diseases (ERN Rare-Liver), General University Hospital, Larissa, Greece.

Frederik Nevens (F)

Division of Hepatology and Liver Transplantation, European Reference Network on Hepatological Diseases (ERN Rare-Liver), University Hospitals KU, Leuven, Belgium.

Nora Cazzagon (N)

Department of Surgery, Oncology and Gastroenterology, European Reference Network on Hepatological Diseases (ERN Rare-Liver), University of Padova, Padova, Italy.

Alessandra Zago (A)

Department of Surgery, Oncology and Gastroenterology, European Reference Network on Hepatological Diseases (ERN Rare-Liver), University of Padova, Padova, Italy.

Francesco Paolo Russo (FP)

Department of Surgery, Oncology and Gastroenterology, European Reference Network on Hepatological Diseases (ERN Rare-Liver), University of Padova, Padova, Italy.

Annarosa Floreani (A)

Department of Surgery, Oncology and Gastroenterology, European Reference Network on Hepatological Diseases (ERN Rare-Liver), University of Padova, Padova, Italy.

Nadir Abbas (N)

Liver Unit, University Hospitals Birmingham National Health Service Foundation Trust Queen Elizabeth, Birmingham, United Kingdom.

Palak Trivedi (P)

National Institute for Health Research (NIHR) Birmingham Biomedical Research Centre (BRC), Institute of Immunology and Immunotherapy, Centre for Liver and Gastrointestinal Research, University of Birmingham, Birmingham B15 2TT, United Kingdom.

Douglas Thorburn (D)

University College London Institute for Liver and Digestive Health, Royal Free Hospital, London, United Kingdom.

Francesca Saffioti (F)

University College London Institute for Liver and Digestive Health, Royal Free Hospital, London, United Kingdom.

Laszlo Barkai (L)

University College London Institute for Liver and Digestive Health, Royal Free Hospital, London, United Kingdom.

Davide Roccarina (D)

University College London Institute for Liver and Digestive Health, Royal Free Hospital, London, United Kingdom.

Vicenza Calvaruso (V)

Section of Gastroenterology and Hepatology, PROMISE, University of Palermo, Palermo, Italy.

Anna Fichera (A)

Section of Gastroenterology and Hepatology, PROMISE, University of Palermo, Palermo, Italy.

Adèle Delamarre (A)

Department of Hepatology, University Hospitals of Bordeaux, Pessac, France.

Natalia Sobenko (N)

Department of Hepatology & Liver Transplantation, Italian Hospital of Buenos Aires, Argentina.

Alejandra Maria Villamil (AM)

Department of Hepatology & Liver Transplantation, Italian Hospital of Buenos Aires, Argentina.

Esli Medina-Morales (E)

Department of Medicine, Division of Gastroenterology, Beth Israel Deaconess Medical Center, Boston, USA.

Alan Bonder (A)

Department of Medicine, Division of Gastroenterology, Beth Israel Deaconess Medical Center, Boston, USA.

Vilas Patwardhan (V)

Department of Medicine, Division of Gastroenterology, Beth Israel Deaconess Medical Center, Boston, USA.

Cristina Rigamonti (C)

Department of Translational Medicine, Università del Piemonte Orientale and Division of Internal Medicine, AOU Maggiore della Carità, Novara, Italy.

Marco Carbone (M)

Division of Gastroenterology, Center for Autoimmune Liver Diseases, Department of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy.

Pietro Invernizzi (P)

Division of Gastroenterology, Center for Autoimmune Liver Diseases, Department of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy.

Laura Cristoferi (L)

Division of Gastroenterology, Center for Autoimmune Liver Diseases, Department of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy.

Adriaan van der Meer (A)

Department of Gastroenterology and Hepatology, Erasmus University Medical Center, Rotterdam, The Netherlands.

Rozanne de Veer (R)

Department of Gastroenterology and Hepatology, Erasmus University Medical Center, Rotterdam, The Netherlands.

Ehud Zigmond (E)

The Research Center for Digestive Tract and Liver Diseases, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.

Eyal Yehezkel (E)

The Research Center for Digestive Tract and Liver Diseases, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.

Andreas E Kremer (AE)

Department of Gastroenterology and Hepatology, University Hospital Zürich, University of Zürich, Zürich, Switzerland.

Ansgar Deibel (A)

Department of Gastroenterology and Hepatology, University Hospital Zürich, University of Zürich, Zürich, Switzerland.

Tony Bruns (T)

Department of Medicine III, University Hospital RWTH Aachen, European Reference Network on Hepatological Diseases (ERN Rare-Liver), Aachen, Germany.

Karsten Große (K)

Department of Medicine III, University Hospital RWTH Aachen, European Reference Network on Hepatological Diseases (ERN Rare-Liver), Aachen, Germany.

Aaron Wetten (A)

Department of Hepatology and Liver Transplantation, Newcastle upon Tyne Hospitals NHS Foundation Trust, Translational and Clinical Research Institute, Newcastle University, United Kingdom.

Jessica Katharine Dyson (JK)

Department of Hepatology and Liver Transplantation, Newcastle upon Tyne Hospitals NHS Foundation Trust, Translational and Clinical Research Institute, Newcastle University, United Kingdom.

David Jones (D)

Department of Hepatology and Liver Transplantation, Newcastle upon Tyne Hospitals NHS Foundation Trust, Translational and Clinical Research Institute, Newcastle University, United Kingdom.

Cynthia Levy (C)

Division of Digestive Health and Liver Diseases, Schiff Center for Liver Diseases, Miami University, United States.

Atsushi Tanaka (A)

Department of Medicine, Teikyo University, Japan.

Jérôme Dumortier (J)

Department of Gastroenterology and Hepatology, Edouard Herriot Hospital, Hospices Civils de Lyon, Claude Bernard University, Lyon, France.

Georges-Philippe Pageaux (GP)

Department of Hepatology and Liver Transplantation, University Hospital, Montpellier, France.

Victor de Lédinghen (V)

Department of Hepatology, University Hospitals of Bordeaux, Pessac, France.

Fabrice Carrat (F)

Sorbonne University, Inserm, Pierre Louis Institute of Epidemiology and Public Health, Paris; Public Health Unit, Saint-Antoine Hospital, Assistance Publique - Hôpitaux de Paris, European Reference Network on Hepatological Diseases (ERN Rare-Liver), France.

Olivier Chazouilléres (O)

Reference Center for Inflammatory Biliary Diseases and Autoimmune Hepatitis, European Reference Network on Hepatological Diseases (ERN Rare-Liver), Saint-Antoine Hospital, Assistance Publique - Hôpitaux de Paris; Inserm UMR_S938, Saint-Antoine Research Center, Sorbonne University, Paris, France.

Christophe Corpechot (C)

Reference Center for Inflammatory Biliary Diseases and Autoimmune Hepatitis, European Reference Network on Hepatological Diseases (ERN Rare-Liver), Saint-Antoine Hospital, Assistance Publique - Hôpitaux de Paris; Inserm UMR_S938, Saint-Antoine Research Center, Sorbonne University, Paris, France. Electronic address: christophe.corpechot@aphp.fr.

Classifications MeSH